View ValuationCipher Pharmaceuticals 향후 성장Future 기준 점검 2/6Cipher Pharmaceuticals (는) 각각 연간 2.1% 및 8.2% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 0.9% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 14% 로 예상됩니다.핵심 정보2.1%이익 성장률0.88%EPS 성장률Pharmaceuticals 이익 성장23.8%매출 성장률8.2%향후 자기자본이익률13.98%애널리스트 커버리지Low마지막 업데이트12 May 2026최근 향후 성장 업데이트업데이트 없음모든 업데이트 보기Recent updatesBoard Change • Jul 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. Independent Director Doug Deeth was the last director to join the board, commencing their role in 2023. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.공시 • Apr 30Cipher Pharmaceuticals Inc. to Report Q1, 2026 Results on May 07, 2026Cipher Pharmaceuticals Inc. announced that they will report Q1, 2026 results After-Market on May 07, 2026공시 • Apr 21Cipher Pharmaceuticals Inc., Annual General Meeting, Jun 18, 2026Cipher Pharmaceuticals Inc., Annual General Meeting, Jun 18, 2026. Location: ontario, toronto Canada공시 • Mar 05Cipher Pharmaceuticals Inc. to Report Q4, 2025 Results on Mar 12, 2026Cipher Pharmaceuticals Inc. announced that they will report Q4, 2025 results at 4:00 PM, US Eastern Standard Time on Mar 12, 2026공시 • Jan 29Cipher Pharmaceuticals Announces Health Canada's Acceptance for Review of New Drug Submission for Natroba™? (Spinosad)Cipher Pharmaceuticals Inc. announced that Health Canada has accepted for review Cipher's new drug submission ("NDS") for Natroba™? (Spinosad), for the treatment of head lice and scabies. Natroba™? (Spinosad) is widely recognized as one of the most effective treatments for the two parasitic indications of head lice and sc babies in the U.S. It is superior to the widely used permethrin 1% for treating head lice and is the only treatment in the U.S. that meets the FDA's criteria for a " complete cure" (elimination of all signs and symptoms) in eradicating sc babies infestations with a single application. Cipher acquired Natroba™? (spinosad) in July 2024, and since acquisition has marketed and distributed the product in the United States ("U.S.) market, through its commercial infrastructure.공시 • Oct 30Cipher Pharmaceuticals Inc. to Report Q3, 2025 Results on Nov 06, 2025Cipher Pharmaceuticals Inc. announced that they will report Q3, 2025 results After-Market on Nov 06, 2025공시 • Aug 28Cipher Pharmaceuticals Inc. Announces the Passing of Board Director and Chairman of Audit Committee Harold M. WolkinCipher Pharmaceuticals Inc. announced the passing of Harold M. Wolkin, a valued member of the Company's Board of Directors and Chairman of the Audit Committee. Mr. Wolkin was a very active member of the Board and his deep understanding of the capital markets and unwavering commitment to the Company's growth and governance were tremendously valuable to the Company. During his tenure, he played a vital role in guiding strategic initiatives, supporting management, and representing the Company and its shareholders with integrity. Harold was a very well-known and highly respective member of the Canadian capital markets community and he will truly be missed by those that knew him.공시 • Jul 29Cipher Pharmaceuticals Inc. to Report Q2, 2025 Results on Aug 07, 2025Cipher Pharmaceuticals Inc. announced that they will report Q2, 2025 results at 4:00 PM, US Eastern Standard Time on Aug 07, 2025공시 • May 03Cipher Pharmaceuticals Inc. to Report Q1, 2025 Results on May 08, 2025Cipher Pharmaceuticals Inc. announced that they will report Q1, 2025 results After-Market on May 08, 2025공시 • Apr 09Cipher Pharmaceuticals Inc., Annual General Meeting, Jun 13, 2025Cipher Pharmaceuticals Inc., Annual General Meeting, Jun 13, 2025. Location: ontario, toronto Canada공시 • Mar 12Cipher Pharmaceuticals Inc. to Report Q4, 2024 Results on Mar 18, 2025Cipher Pharmaceuticals Inc. announced that they will report Q4, 2024 results at 4:00 PM, US Eastern Standard Time on Mar 18, 2025Valuation Update With 7 Day Price Move • Nov 14Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to €8.55, the stock trades at a forward P/E ratio of 12x. Average forward P/E is 14x in the Pharmaceuticals industry in Germany. Total returns to shareholders of 466% over the past three years.Reported Earnings • Nov 10Third quarter 2024 earnings released: EPS: US$0.011 (vs US$0.28 in 3Q 2023)Third quarter 2024 results: EPS: US$0.011 (down from US$0.28 in 3Q 2023). Revenue: US$10.4m (up 71% from 3Q 2023). Net income: US$283.0k (down 96% from 3Q 2023). Profit margin: 2.7% (down from 116% in 3Q 2023). Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 3.4% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has increased by 89% per year, which means it is tracking significantly ahead of earnings growth.New Risk • Nov 10New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 101% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (101% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (9.8% average weekly change). Profit margins are more than 30% lower than last year (60% net profit margin). Shareholders have been diluted in the past year (6.5% increase in shares outstanding).공시 • Nov 04Cipher Pharmaceuticals Inc. to Report Q3, 2024 Results on Nov 07, 2024Cipher Pharmaceuticals Inc. announced that they will report Q3, 2024 results After-Market on Nov 07, 2024공시 • Oct 08Cipher Pharmaceuticals Inc. Appoints Hamed Ghanei as Chief Business OfficerCipher Pharmaceuticals Inc. announced the appointment of Hamed Ghanei as Chief Business Officer. Dr. Ghanei has over 15 years of experience in specialty pharmaceuticals, venture funds, and healthcare investment banking. Throughout his career, he has led the evaluation of over 500 licensing and M&A opportunities and has been involved in five commercial product launches. He has successfully negotiated over 20 transactions with total value exceeding $1 billion. Dr. Ghanei holds a B.Sc. from the University of Waterloo, a M.Sc. in Microbiology and Biochemistry from the University of Guelph, and a Ph.D. in Medical Biophysics from the University of Toronto.Valuation Update With 7 Day Price Move • Oct 04Investor sentiment improves as stock rises 15%After last week's 15% share price gain to €10.20, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 14x in the Pharmaceuticals industry in Germany. Total returns to shareholders of 534% over the past three years.Valuation Update With 7 Day Price Move • Sep 13Investor sentiment deteriorates as stock falls 21%After last week's 21% share price decline to €9.35, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 15x in the Pharmaceuticals industry in Germany. Total returns to shareholders of 483% over the past three years.Valuation Update With 7 Day Price Move • Aug 20Investor sentiment improves as stock rises 18%After last week's 18% share price gain to €10.40, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 17x in the Pharmaceuticals industry in Germany. Total returns to shareholders of 584% over the past three years.공시 • Aug 09+ 1 more updateCipher Pharmaceuticals Inc. Announces CFO ChangesEffective August 10, 2024, and as a result of the Natroba Acquisition, Cipher Pharmaceuticals Inc.'s Chief Financial Officer, Bryan Jacobs, will assume the title of President of the Company. His mandate will be to manage the transition and integration of the U.S. operations and commercial sales team. The Company's Vice President, Finance, Ryan Mailling, has in turn been appointed as the Chief Financial Officer of the Company, taking over from Mr. Jacobs.Reported Earnings • Aug 09Second quarter 2024 earnings released: EPS: US$0.12 (vs US$0.12 in 2Q 2023)Second quarter 2024 results: EPS: US$0.12 (down from US$0.12 in 2Q 2023). Revenue: US$5.30m (flat on 2Q 2023). Net income: US$3.00m (down 2.5% from 2Q 2023). Profit margin: 56% (down from 58% in 2Q 2023). Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 3.8% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 49% per year but the company’s share price has increased by 102% per year, which means it is tracking significantly ahead of earnings growth.공시 • Aug 02Cipher Pharmaceuticals Inc. to Report Q2, 2024 Results on Aug 08, 2024Cipher Pharmaceuticals Inc. announced that they will report Q2, 2024 results After-Market on Aug 08, 2024New Risk • Aug 01New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). High level of non-cash earnings (23% accrual ratio).Valuation Update With 7 Day Price Move • Jul 30Investor sentiment improves as stock rises 16%After last week's 16% share price gain to €6.80, the stock trades at a forward P/E ratio of 11x. Average forward P/E is 17x in the Pharmaceuticals industry in Germany. Total returns to shareholders of 588% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €13.03 per share.Reported Earnings • May 10First quarter 2024 earnings released: EPS: US$0.21 (vs US$0.10 in 1Q 2023)First quarter 2024 results: EPS: US$0.21 (up from US$0.10 in 1Q 2023). Revenue: US$5.87m (up 20% from 1Q 2023). Net income: US$4.92m (up 88% from 1Q 2023). Profit margin: 84% (up from 54% in 1Q 2023). The increase in margin was primarily driven by lower expenses. Revenue is forecast to grow 1.8% p.a. on average during the next 3 years, compared to a 3.4% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 60% per year but the company’s share price has increased by 89% per year, which means it is tracking significantly ahead of earnings growth.공시 • Apr 09Cipher Pharmaceuticals Inc., Annual General Meeting, Jun 14, 2024Cipher Pharmaceuticals Inc., Annual General Meeting, Jun 14, 2024.Valuation Update With 7 Day Price Move • Mar 21Investor sentiment improves as stock rises 25%After last week's 25% share price gain to €5.95, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 15x in the Pharmaceuticals industry in Germany. Total returns to shareholders of 717% over the past three years.Reported Earnings • Mar 15Full year 2023 earnings released: EPS: US$0.81 (vs US$1.05 in FY 2022)Full year 2023 results: EPS: US$0.81 (down from US$1.05 in FY 2022). Revenue: US$21.2m (up 2.4% from FY 2022). Net income: US$20.4m (down 24% from FY 2022). Profit margin: 96% (down from 129% in FY 2022). Revenue is forecast to grow 2.2% p.a. on average during the next 3 years, compared to a 3.3% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 69% per year but the company’s share price has increased by 99% per year, which means it is tracking significantly ahead of earnings growth.공시 • Mar 09Cipher Pharmaceuticals Inc. to Report Q4, 2023 Results on Mar 14, 2024Cipher Pharmaceuticals Inc. announced that they will report Q4, 2023 results After-Market on Mar 14, 2024Valuation Update With 7 Day Price Move • Feb 17Investor sentiment improves as stock rises 20%After last week's 20% share price gain to €5.30, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 16x in the Pharmaceuticals industry in Germany. Total returns to shareholders of 772% over the past three years.Valuation Update With 7 Day Price Move • Jan 06Investor sentiment improves as stock rises 16%After last week's 16% share price gain to €4.30, the stock trades at a forward P/E ratio of 13x. Average forward P/E is 17x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 481% over the past three years.Valuation Update With 7 Day Price Move • Nov 16Investor sentiment improves as stock rises 24%After last week's 24% share price gain to €3.62, the stock trades at a forward P/E ratio of 11x. Average forward P/E is 18x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 505% over the past three years.Reported Earnings • Nov 12Third quarter 2023 earnings released: EPS: US$0.28 (vs US$0.11 in 3Q 2022)Third quarter 2023 results: EPS: US$0.28 (up from US$0.11 in 3Q 2022). Revenue: US$6.07m (up 27% from 3Q 2022). Net income: US$7.03m (up 165% from 3Q 2022). Revenue is forecast to stay flat during the next 3 years compared to a 3.6% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 74% per year whereas the company’s share price has increased by 77% per year.공시 • Oct 28Cipher Pharmaceuticals Inc. to Report Q3, 2023 Results on Nov 09, 2023Cipher Pharmaceuticals Inc. announced that they will report Q3, 2023 results on Nov 09, 2023공시 • Sep 06Cipher Pharmaceuticals Inc. (TSX:CPH) announces an Equity Buyback for CAD 6 million worth of its shares.Cipher Pharmaceuticals Inc. (TSX:CPH) announces a share repurchase program. Under the substantial issuer bid, the company will repurchase up to CAD 6 million worth of its outstanding shares. The shares will be tendered at a price of not less than CAD 3.95 per share and not more than CAD 4.75 per share. The company plans to fund the offer from available cash on hand. The shares purchased under the offer will be cancelled. If the aggregate cost to purchase the tendered shares exceeds $6 million, the company will accept such shares on a pro-rata basis after giving effect to “odd lot” tenders, which will not be subject to pro-ration. The bid will expire on October 11, 2023, unless extended or withdrawn.Reported Earnings • Aug 11Second quarter 2023 earnings released: EPS: US$0.12 (vs US$0.085 in 2Q 2022)Second quarter 2023 results: EPS: US$0.12 (up from US$0.085 in 2Q 2022). Revenue: US$5.29m (down 4.9% from 2Q 2022). Net income: US$3.07m (up 43% from 2Q 2022). Profit margin: 58% (up from 39% in 2Q 2022). The increase in margin was driven by lower expenses. Revenue is forecast to stay flat during the next 3 years compared to a 3.1% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 75% per year but the company’s share price has only increased by 43% per year, which means it is significantly lagging earnings growth.공시 • Jul 29Cipher Pharmaceuticals Inc. to Report Q2, 2023 Results on Aug 10, 2023Cipher Pharmaceuticals Inc. announced that they will report Q2, 2023 results on Aug 10, 2023Board Change • Jun 02Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was an independent director. The company's board is composed of: 1 new director. 6 experienced directors. No highly experienced directors. 3 independent directors (4 non-independent directors). Independent Director Cathy Steiner was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Reported Earnings • May 13First quarter 2023 earnings released: EPS: US$0.10 (vs US$0.083 in 1Q 2022)First quarter 2023 results: EPS: US$0.10 (up from US$0.083 in 1Q 2022). Revenue: US$4.89m (down 9.8% from 1Q 2022). Net income: US$2.63m (up 22% from 1Q 2022). Profit margin: 54% (up from 40% in 1Q 2022). The increase in margin was driven by lower expenses. Revenue is forecast to stay flat during the next 3 years compared to a 3.8% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 71% per year but the company’s share price has only increased by 47% per year, which means it is significantly lagging earnings growth.공시 • May 05Cipher Pharmaceuticals Inc. to Report Q1, 2023 Results on May 11, 2023Cipher Pharmaceuticals Inc. announced that they will report Q1, 2023 results on May 11, 2023Reported Earnings • Mar 17Full year 2022 earnings released: EPS: US$1.05 (vs US$0.29 in FY 2021)Full year 2022 results: EPS: US$1.05 (up from US$0.29 in FY 2021). Revenue: US$20.7m (down 5.8% from FY 2021). Net income: US$26.6m (up 243% from FY 2021). Revenue is forecast to grow 2.9% p.a. on average during the next 2 years, compared to a 3.4% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 63% per year but the company’s share price has increased by 105% per year, which means it is tracking significantly ahead of earnings growth.공시 • Feb 14Cipher Pharmaceuticals Inc. Declares Quarterly Dividend, Payable on or About February 28, 2023On February 10, 2022, the Board of Directors of Cipher Pharmaceuticals Inc. declared a quarterly dividend of $0.0.01875 per share to shareholders of record on February 21, 2023, payable on or about February 28, 2023.Recent Insider Transactions • Dec 18Independent Director recently sold €56k worth of stockOn the 9th of December, Christian Godin sold around 21k shares on-market at roughly €2.65 per share. This transaction amounted to 18% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €32k more than they bought in the last 12 months.Reported Earnings • Nov 16Third quarter 2022 earnings released: EPS: US$0.11 (vs US$0.03 in 3Q 2021)Third quarter 2022 results: EPS: US$0.11 (up from US$0.03 in 3Q 2021). Revenue: US$4.79m (up 6.2% from 3Q 2021). Net income: US$2.65m (up 233% from 3Q 2021). Profit margin: 55% (up from 18% in 3Q 2021). The increase in margin was primarily driven by lower expenses. Revenue is forecast to stay flat during the next 3 years compared to a 3.9% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 48% per year whereas the company’s share price has increased by 45% per year.Reported Earnings • Nov 12Third quarter 2022 earnings released: EPS: US$0.11 (vs US$0.03 in 3Q 2021)Third quarter 2022 results: EPS: US$0.11 (up from US$0.03 in 3Q 2021). Revenue: US$4.79m (up 6.2% from 3Q 2021). Net income: US$2.65m (up 233% from 3Q 2021). Profit margin: 55% (up from 18% in 3Q 2021). The increase in margin was primarily driven by lower expenses. Revenue is forecast to stay flat during the next 3 years compared to a 4.1% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 48% per year whereas the company’s share price has increased by 46% per year.Reported Earnings • Aug 13Second quarter 2022 earnings released: EPS: US$0.08 (vs US$0.10 in 2Q 2021)Second quarter 2022 results: EPS: US$0.08 (down from US$0.10 in 2Q 2021). Revenue: US$5.56m (down 9.3% from 2Q 2021). Net income: US$2.15m (down 24% from 2Q 2021). Profit margin: 39% (down from 46% in 2Q 2021). The decrease in margin was primarily driven by lower revenue. Over the next year, revenue is forecast to grow 9.6%, compared to a 6.3% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 47% per year but the company’s share price has only increased by 29% per year, which means it is significantly lagging earnings growth.Reported Earnings • May 14First quarter 2022 earnings released: EPS: US$0.08 (vs US$0.05 in 1Q 2021)First quarter 2022 results: EPS: US$0.08 (up from US$0.05 in 1Q 2021). Revenue: US$5.42m (flat on 1Q 2021). Net income: US$2.15m (up 61% from 1Q 2021). Profit margin: 40% (up from 25% in 1Q 2021). Over the next year, revenue is forecast to grow 7.0%, compared to a 7.1% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 45% per year but the company’s share price has only increased by 24% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • Mar 24Investor sentiment improved over the past weekAfter last week's 15% share price gain to €1.64, the stock trades at a forward P/E ratio of 5x. Average forward P/E is 20x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 70% over the past three years.Reported Earnings • Mar 19Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: EPS: US$0.29 (up from US$0.16 in FY 2020). Revenue: US$21.9m (up 1.6% from FY 2020). Net income: US$7.76m (up 77% from FY 2020). Profit margin: 35% (up from 20% in FY 2020). The increase in margin was primarily driven by lower expenses. Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 8.5%, compared to a 8.2% growth forecast for the pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 45% per year but the company’s share price has only increased by 16% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • Feb 09Investor sentiment improved over the past weekAfter last week's 19% share price gain to €1.45, the stock trades at a forward P/E ratio of 5x. Average forward P/E is 19x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 19% over the past three years.Valuation Update With 7 Day Price Move • Dec 25Investor sentiment improved over the past weekAfter last week's 16% share price gain to €1.28, the stock trades at a forward P/E ratio of 4x. Average forward P/E is 21x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 25% over the past three years.Reported Earnings • Nov 12Third quarter 2021 earnings released: EPS US$0.03 (vs US$0.059 in 3Q 2020)The company reported a poor third quarter result with weaker earnings, revenues and profit margins. Third quarter 2021 results: Revenue: US$4.51m (down 6.9% from 3Q 2020). Net income: US$796.0k (down 50% from 3Q 2020). Profit margin: 18% (down from 33% in 3Q 2020). Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has only increased by 12% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • Sep 14Investor sentiment improved over the past weekAfter last week's 17% share price gain to €1.60, the stock trades at a forward P/E ratio of 6x. Average forward P/E is 24x in the Pharmaceuticals industry in Europe. Total loss to shareholders of 23% over the past three years.Valuation Update With 7 Day Price Move • Aug 19Investor sentiment improved over the past weekAfter last week's 19% share price gain to US$1.34, the stock trades at a forward P/E ratio of 4x. Average forward P/E is 25x in the Pharmaceuticals industry in Europe. Total loss to shareholders of 35% over the past three years.Reported Earnings • Aug 14Second quarter 2021 earnings released: EPS US$0.11 (vs US$0.015 in 2Q 2020)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: US$6.13m (up 30% from 2Q 2020). Net income: US$2.82m (up US$2.41m from 2Q 2020). Profit margin: 46% (up from 8.7% in 2Q 2020). Over the last 3 years on average, earnings per share has remained flat but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings.Valuation Update With 7 Day Price Move • Jun 08Investor sentiment improved over the past weekAfter last week's 20% share price gain to US$1.06, the stock trades at a forward P/E ratio of 5x. Average forward P/E is 24x in the Pharmaceuticals industry in Europe. Total loss to shareholders of 38% over the past three years.Reported Earnings • May 16First quarter 2021 earnings released: EPS US$0.05 (vs US$0.092 in 1Q 2020)The company reported a poor first quarter result with weaker earnings, revenues and profit margins. First quarter 2021 results: Revenue: US$5.45m (down 7.7% from 1Q 2020). Net income: US$1.34m (down 46% from 1Q 2020). Profit margin: 25% (down from 42% in 1Q 2020). Over the last 3 years on average, earnings per share has fallen by 27% per year and the company’s share price has also fallen by 27% per year.Is New 90 Day High Low • Jan 08New 90-day high: €0.74The company is up 9.0% from its price of €0.68 on 09 October 2020. The German market is up 8.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Pharmaceuticals industry, which is up 11% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €1.71 per share.Reported Earnings • Nov 14Third quarter 2020 earnings released: EPS US$0.06The company reported a decent third quarter result with improved earnings and profit margins, although revenues were weaker. Third quarter 2020 results: Revenue: US$4.85m (down 16% from 3Q 2019). Net income: US$1.60m (up US$3.79m from 3Q 2019). Profit margin: 33% (up from net loss in 3Q 2019). The move to profitability was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 45% per year whereas the company’s share price has fallen by 40% per year.Analyst Estimate Surprise Post Earnings • Nov 14Revenue beats expectationsRevenue exceeded analyst estimates by 23%. Over the next year, revenue is expected to shrink by 24% compared to a 2.8% growth forecast for the Pharmaceuticals industry in Germany.Is New 90 Day High Low • Nov 10New 90-day low: €0.59The company is down 32% from its price of €0.87 on 12 August 2020. The German market is flat over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 2.0% over the same period.Is New 90 Day High Low • Oct 21New 90-day low: €0.64The company is down 31% from its price of €0.92 on 23 July 2020. The German market is down 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 10.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €2.55 per share.공시 • Oct 10Cipher Pharmaceuticals Inc. Approves the Appointment of Cathy Steiner as DirectorCipher Pharmaceuticals Inc. announced the voting results for the election of directors at its Annual Meeting of Shareholders held earlier October 8, 2020. The shareholders approved the appointment of Cathy Steiner as director.Is New 90 Day High Low • Sep 28New 90-day low: €0.69The company is down 10.0% from its price of €0.77 on 30 June 2020. The German market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 4.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €2.58 per share.이익 및 매출 성장 예측DB:PHE - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/20286527N/A40212/31/20276226N/A39312/31/20265322302843/31/202651312930N/A12/31/202550273030N/A9/30/202550173030N/A6/30/20254812-5921N/A3/31/2025409-5921N/A12/31/20243312-6020N/A9/30/20242616-6713N/A6/30/202422231717N/A3/31/202422231414N/A12/31/202321201616N/A9/30/202321321515N/A6/30/202320281313N/A3/31/202320271313N/A12/31/202221271111N/A9/30/202222101515N/A6/30/20222181111N/A3/31/20222291111N/A12/31/20212281414N/A9/30/20212251414N/A6/30/20212361212N/A3/31/20212131111N/A12/31/20202241112N/A9/30/202021777N/A6/30/20202231011N/A3/31/20202341112N/A12/31/2019223N/A8N/A9/30/201923-1N/A8N/A6/30/2019222N/A6N/A3/31/2019233N/A2N/A12/31/2018231N/A8N/A9/30/2018286N/A13N/A6/30/2018349N/A18N/A3/31/20183711N/A19N/A12/31/20174011N/A13N/A9/30/2017347N/A11N/A6/30/2017325N/A9N/A3/31/2017311N/A10N/A12/31/2016304N/A11N/A9/30/2016336N/A8N/A6/30/2016342N/A7N/A3/31/2016341N/A7N/A12/31/2015342N/A8N/A9/30/2015323N/A12N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: PHE 의 연간 예상 수익 증가율(2.1%)이 saving rate(1.9%)보다 높습니다.수익 vs 시장: PHE 의 연간 수익(2.1%)이 German 시장(16.9%)보다 느리게 성장할 것으로 예상됩니다.고성장 수익: PHE 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.수익 대 시장: PHE 의 수익(연간 8.2%)이 German 시장(연간 6.7%)보다 빠르게 성장할 것으로 예상됩니다.고성장 매출: PHE 의 수익(연간 8.2%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: PHE의 자본 수익률은 3년 후 14%로 낮을 것으로 예상됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/07/11 02:22종가2026/07/10 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Cipher Pharmaceuticals Inc.는 8명의 분석가가 다루고 있습니다. 이 중 4명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관David NovakATB Cormark Historical (Cormark Securities)Tania Armstrong-WhitworthCanaccord GenuityPrakash GowdCIBC Capital Markets5명의 분석가 더 보기
Board Change • Jul 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. Independent Director Doug Deeth was the last director to join the board, commencing their role in 2023. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
공시 • Apr 30Cipher Pharmaceuticals Inc. to Report Q1, 2026 Results on May 07, 2026Cipher Pharmaceuticals Inc. announced that they will report Q1, 2026 results After-Market on May 07, 2026
공시 • Apr 21Cipher Pharmaceuticals Inc., Annual General Meeting, Jun 18, 2026Cipher Pharmaceuticals Inc., Annual General Meeting, Jun 18, 2026. Location: ontario, toronto Canada
공시 • Mar 05Cipher Pharmaceuticals Inc. to Report Q4, 2025 Results on Mar 12, 2026Cipher Pharmaceuticals Inc. announced that they will report Q4, 2025 results at 4:00 PM, US Eastern Standard Time on Mar 12, 2026
공시 • Jan 29Cipher Pharmaceuticals Announces Health Canada's Acceptance for Review of New Drug Submission for Natroba™? (Spinosad)Cipher Pharmaceuticals Inc. announced that Health Canada has accepted for review Cipher's new drug submission ("NDS") for Natroba™? (Spinosad), for the treatment of head lice and scabies. Natroba™? (Spinosad) is widely recognized as one of the most effective treatments for the two parasitic indications of head lice and sc babies in the U.S. It is superior to the widely used permethrin 1% for treating head lice and is the only treatment in the U.S. that meets the FDA's criteria for a " complete cure" (elimination of all signs and symptoms) in eradicating sc babies infestations with a single application. Cipher acquired Natroba™? (spinosad) in July 2024, and since acquisition has marketed and distributed the product in the United States ("U.S.) market, through its commercial infrastructure.
공시 • Oct 30Cipher Pharmaceuticals Inc. to Report Q3, 2025 Results on Nov 06, 2025Cipher Pharmaceuticals Inc. announced that they will report Q3, 2025 results After-Market on Nov 06, 2025
공시 • Aug 28Cipher Pharmaceuticals Inc. Announces the Passing of Board Director and Chairman of Audit Committee Harold M. WolkinCipher Pharmaceuticals Inc. announced the passing of Harold M. Wolkin, a valued member of the Company's Board of Directors and Chairman of the Audit Committee. Mr. Wolkin was a very active member of the Board and his deep understanding of the capital markets and unwavering commitment to the Company's growth and governance were tremendously valuable to the Company. During his tenure, he played a vital role in guiding strategic initiatives, supporting management, and representing the Company and its shareholders with integrity. Harold was a very well-known and highly respective member of the Canadian capital markets community and he will truly be missed by those that knew him.
공시 • Jul 29Cipher Pharmaceuticals Inc. to Report Q2, 2025 Results on Aug 07, 2025Cipher Pharmaceuticals Inc. announced that they will report Q2, 2025 results at 4:00 PM, US Eastern Standard Time on Aug 07, 2025
공시 • May 03Cipher Pharmaceuticals Inc. to Report Q1, 2025 Results on May 08, 2025Cipher Pharmaceuticals Inc. announced that they will report Q1, 2025 results After-Market on May 08, 2025
공시 • Apr 09Cipher Pharmaceuticals Inc., Annual General Meeting, Jun 13, 2025Cipher Pharmaceuticals Inc., Annual General Meeting, Jun 13, 2025. Location: ontario, toronto Canada
공시 • Mar 12Cipher Pharmaceuticals Inc. to Report Q4, 2024 Results on Mar 18, 2025Cipher Pharmaceuticals Inc. announced that they will report Q4, 2024 results at 4:00 PM, US Eastern Standard Time on Mar 18, 2025
Valuation Update With 7 Day Price Move • Nov 14Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to €8.55, the stock trades at a forward P/E ratio of 12x. Average forward P/E is 14x in the Pharmaceuticals industry in Germany. Total returns to shareholders of 466% over the past three years.
Reported Earnings • Nov 10Third quarter 2024 earnings released: EPS: US$0.011 (vs US$0.28 in 3Q 2023)Third quarter 2024 results: EPS: US$0.011 (down from US$0.28 in 3Q 2023). Revenue: US$10.4m (up 71% from 3Q 2023). Net income: US$283.0k (down 96% from 3Q 2023). Profit margin: 2.7% (down from 116% in 3Q 2023). Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 3.4% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has increased by 89% per year, which means it is tracking significantly ahead of earnings growth.
New Risk • Nov 10New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 101% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (101% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (9.8% average weekly change). Profit margins are more than 30% lower than last year (60% net profit margin). Shareholders have been diluted in the past year (6.5% increase in shares outstanding).
공시 • Nov 04Cipher Pharmaceuticals Inc. to Report Q3, 2024 Results on Nov 07, 2024Cipher Pharmaceuticals Inc. announced that they will report Q3, 2024 results After-Market on Nov 07, 2024
공시 • Oct 08Cipher Pharmaceuticals Inc. Appoints Hamed Ghanei as Chief Business OfficerCipher Pharmaceuticals Inc. announced the appointment of Hamed Ghanei as Chief Business Officer. Dr. Ghanei has over 15 years of experience in specialty pharmaceuticals, venture funds, and healthcare investment banking. Throughout his career, he has led the evaluation of over 500 licensing and M&A opportunities and has been involved in five commercial product launches. He has successfully negotiated over 20 transactions with total value exceeding $1 billion. Dr. Ghanei holds a B.Sc. from the University of Waterloo, a M.Sc. in Microbiology and Biochemistry from the University of Guelph, and a Ph.D. in Medical Biophysics from the University of Toronto.
Valuation Update With 7 Day Price Move • Oct 04Investor sentiment improves as stock rises 15%After last week's 15% share price gain to €10.20, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 14x in the Pharmaceuticals industry in Germany. Total returns to shareholders of 534% over the past three years.
Valuation Update With 7 Day Price Move • Sep 13Investor sentiment deteriorates as stock falls 21%After last week's 21% share price decline to €9.35, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 15x in the Pharmaceuticals industry in Germany. Total returns to shareholders of 483% over the past three years.
Valuation Update With 7 Day Price Move • Aug 20Investor sentiment improves as stock rises 18%After last week's 18% share price gain to €10.40, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 17x in the Pharmaceuticals industry in Germany. Total returns to shareholders of 584% over the past three years.
공시 • Aug 09+ 1 more updateCipher Pharmaceuticals Inc. Announces CFO ChangesEffective August 10, 2024, and as a result of the Natroba Acquisition, Cipher Pharmaceuticals Inc.'s Chief Financial Officer, Bryan Jacobs, will assume the title of President of the Company. His mandate will be to manage the transition and integration of the U.S. operations and commercial sales team. The Company's Vice President, Finance, Ryan Mailling, has in turn been appointed as the Chief Financial Officer of the Company, taking over from Mr. Jacobs.
Reported Earnings • Aug 09Second quarter 2024 earnings released: EPS: US$0.12 (vs US$0.12 in 2Q 2023)Second quarter 2024 results: EPS: US$0.12 (down from US$0.12 in 2Q 2023). Revenue: US$5.30m (flat on 2Q 2023). Net income: US$3.00m (down 2.5% from 2Q 2023). Profit margin: 56% (down from 58% in 2Q 2023). Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 3.8% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 49% per year but the company’s share price has increased by 102% per year, which means it is tracking significantly ahead of earnings growth.
공시 • Aug 02Cipher Pharmaceuticals Inc. to Report Q2, 2024 Results on Aug 08, 2024Cipher Pharmaceuticals Inc. announced that they will report Q2, 2024 results After-Market on Aug 08, 2024
New Risk • Aug 01New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). High level of non-cash earnings (23% accrual ratio).
Valuation Update With 7 Day Price Move • Jul 30Investor sentiment improves as stock rises 16%After last week's 16% share price gain to €6.80, the stock trades at a forward P/E ratio of 11x. Average forward P/E is 17x in the Pharmaceuticals industry in Germany. Total returns to shareholders of 588% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €13.03 per share.
Reported Earnings • May 10First quarter 2024 earnings released: EPS: US$0.21 (vs US$0.10 in 1Q 2023)First quarter 2024 results: EPS: US$0.21 (up from US$0.10 in 1Q 2023). Revenue: US$5.87m (up 20% from 1Q 2023). Net income: US$4.92m (up 88% from 1Q 2023). Profit margin: 84% (up from 54% in 1Q 2023). The increase in margin was primarily driven by lower expenses. Revenue is forecast to grow 1.8% p.a. on average during the next 3 years, compared to a 3.4% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 60% per year but the company’s share price has increased by 89% per year, which means it is tracking significantly ahead of earnings growth.
공시 • Apr 09Cipher Pharmaceuticals Inc., Annual General Meeting, Jun 14, 2024Cipher Pharmaceuticals Inc., Annual General Meeting, Jun 14, 2024.
Valuation Update With 7 Day Price Move • Mar 21Investor sentiment improves as stock rises 25%After last week's 25% share price gain to €5.95, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 15x in the Pharmaceuticals industry in Germany. Total returns to shareholders of 717% over the past three years.
Reported Earnings • Mar 15Full year 2023 earnings released: EPS: US$0.81 (vs US$1.05 in FY 2022)Full year 2023 results: EPS: US$0.81 (down from US$1.05 in FY 2022). Revenue: US$21.2m (up 2.4% from FY 2022). Net income: US$20.4m (down 24% from FY 2022). Profit margin: 96% (down from 129% in FY 2022). Revenue is forecast to grow 2.2% p.a. on average during the next 3 years, compared to a 3.3% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 69% per year but the company’s share price has increased by 99% per year, which means it is tracking significantly ahead of earnings growth.
공시 • Mar 09Cipher Pharmaceuticals Inc. to Report Q4, 2023 Results on Mar 14, 2024Cipher Pharmaceuticals Inc. announced that they will report Q4, 2023 results After-Market on Mar 14, 2024
Valuation Update With 7 Day Price Move • Feb 17Investor sentiment improves as stock rises 20%After last week's 20% share price gain to €5.30, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 16x in the Pharmaceuticals industry in Germany. Total returns to shareholders of 772% over the past three years.
Valuation Update With 7 Day Price Move • Jan 06Investor sentiment improves as stock rises 16%After last week's 16% share price gain to €4.30, the stock trades at a forward P/E ratio of 13x. Average forward P/E is 17x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 481% over the past three years.
Valuation Update With 7 Day Price Move • Nov 16Investor sentiment improves as stock rises 24%After last week's 24% share price gain to €3.62, the stock trades at a forward P/E ratio of 11x. Average forward P/E is 18x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 505% over the past three years.
Reported Earnings • Nov 12Third quarter 2023 earnings released: EPS: US$0.28 (vs US$0.11 in 3Q 2022)Third quarter 2023 results: EPS: US$0.28 (up from US$0.11 in 3Q 2022). Revenue: US$6.07m (up 27% from 3Q 2022). Net income: US$7.03m (up 165% from 3Q 2022). Revenue is forecast to stay flat during the next 3 years compared to a 3.6% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 74% per year whereas the company’s share price has increased by 77% per year.
공시 • Oct 28Cipher Pharmaceuticals Inc. to Report Q3, 2023 Results on Nov 09, 2023Cipher Pharmaceuticals Inc. announced that they will report Q3, 2023 results on Nov 09, 2023
공시 • Sep 06Cipher Pharmaceuticals Inc. (TSX:CPH) announces an Equity Buyback for CAD 6 million worth of its shares.Cipher Pharmaceuticals Inc. (TSX:CPH) announces a share repurchase program. Under the substantial issuer bid, the company will repurchase up to CAD 6 million worth of its outstanding shares. The shares will be tendered at a price of not less than CAD 3.95 per share and not more than CAD 4.75 per share. The company plans to fund the offer from available cash on hand. The shares purchased under the offer will be cancelled. If the aggregate cost to purchase the tendered shares exceeds $6 million, the company will accept such shares on a pro-rata basis after giving effect to “odd lot” tenders, which will not be subject to pro-ration. The bid will expire on October 11, 2023, unless extended or withdrawn.
Reported Earnings • Aug 11Second quarter 2023 earnings released: EPS: US$0.12 (vs US$0.085 in 2Q 2022)Second quarter 2023 results: EPS: US$0.12 (up from US$0.085 in 2Q 2022). Revenue: US$5.29m (down 4.9% from 2Q 2022). Net income: US$3.07m (up 43% from 2Q 2022). Profit margin: 58% (up from 39% in 2Q 2022). The increase in margin was driven by lower expenses. Revenue is forecast to stay flat during the next 3 years compared to a 3.1% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 75% per year but the company’s share price has only increased by 43% per year, which means it is significantly lagging earnings growth.
공시 • Jul 29Cipher Pharmaceuticals Inc. to Report Q2, 2023 Results on Aug 10, 2023Cipher Pharmaceuticals Inc. announced that they will report Q2, 2023 results on Aug 10, 2023
Board Change • Jun 02Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was an independent director. The company's board is composed of: 1 new director. 6 experienced directors. No highly experienced directors. 3 independent directors (4 non-independent directors). Independent Director Cathy Steiner was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Reported Earnings • May 13First quarter 2023 earnings released: EPS: US$0.10 (vs US$0.083 in 1Q 2022)First quarter 2023 results: EPS: US$0.10 (up from US$0.083 in 1Q 2022). Revenue: US$4.89m (down 9.8% from 1Q 2022). Net income: US$2.63m (up 22% from 1Q 2022). Profit margin: 54% (up from 40% in 1Q 2022). The increase in margin was driven by lower expenses. Revenue is forecast to stay flat during the next 3 years compared to a 3.8% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 71% per year but the company’s share price has only increased by 47% per year, which means it is significantly lagging earnings growth.
공시 • May 05Cipher Pharmaceuticals Inc. to Report Q1, 2023 Results on May 11, 2023Cipher Pharmaceuticals Inc. announced that they will report Q1, 2023 results on May 11, 2023
Reported Earnings • Mar 17Full year 2022 earnings released: EPS: US$1.05 (vs US$0.29 in FY 2021)Full year 2022 results: EPS: US$1.05 (up from US$0.29 in FY 2021). Revenue: US$20.7m (down 5.8% from FY 2021). Net income: US$26.6m (up 243% from FY 2021). Revenue is forecast to grow 2.9% p.a. on average during the next 2 years, compared to a 3.4% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 63% per year but the company’s share price has increased by 105% per year, which means it is tracking significantly ahead of earnings growth.
공시 • Feb 14Cipher Pharmaceuticals Inc. Declares Quarterly Dividend, Payable on or About February 28, 2023On February 10, 2022, the Board of Directors of Cipher Pharmaceuticals Inc. declared a quarterly dividend of $0.0.01875 per share to shareholders of record on February 21, 2023, payable on or about February 28, 2023.
Recent Insider Transactions • Dec 18Independent Director recently sold €56k worth of stockOn the 9th of December, Christian Godin sold around 21k shares on-market at roughly €2.65 per share. This transaction amounted to 18% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €32k more than they bought in the last 12 months.
Reported Earnings • Nov 16Third quarter 2022 earnings released: EPS: US$0.11 (vs US$0.03 in 3Q 2021)Third quarter 2022 results: EPS: US$0.11 (up from US$0.03 in 3Q 2021). Revenue: US$4.79m (up 6.2% from 3Q 2021). Net income: US$2.65m (up 233% from 3Q 2021). Profit margin: 55% (up from 18% in 3Q 2021). The increase in margin was primarily driven by lower expenses. Revenue is forecast to stay flat during the next 3 years compared to a 3.9% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 48% per year whereas the company’s share price has increased by 45% per year.
Reported Earnings • Nov 12Third quarter 2022 earnings released: EPS: US$0.11 (vs US$0.03 in 3Q 2021)Third quarter 2022 results: EPS: US$0.11 (up from US$0.03 in 3Q 2021). Revenue: US$4.79m (up 6.2% from 3Q 2021). Net income: US$2.65m (up 233% from 3Q 2021). Profit margin: 55% (up from 18% in 3Q 2021). The increase in margin was primarily driven by lower expenses. Revenue is forecast to stay flat during the next 3 years compared to a 4.1% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 48% per year whereas the company’s share price has increased by 46% per year.
Reported Earnings • Aug 13Second quarter 2022 earnings released: EPS: US$0.08 (vs US$0.10 in 2Q 2021)Second quarter 2022 results: EPS: US$0.08 (down from US$0.10 in 2Q 2021). Revenue: US$5.56m (down 9.3% from 2Q 2021). Net income: US$2.15m (down 24% from 2Q 2021). Profit margin: 39% (down from 46% in 2Q 2021). The decrease in margin was primarily driven by lower revenue. Over the next year, revenue is forecast to grow 9.6%, compared to a 6.3% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 47% per year but the company’s share price has only increased by 29% per year, which means it is significantly lagging earnings growth.
Reported Earnings • May 14First quarter 2022 earnings released: EPS: US$0.08 (vs US$0.05 in 1Q 2021)First quarter 2022 results: EPS: US$0.08 (up from US$0.05 in 1Q 2021). Revenue: US$5.42m (flat on 1Q 2021). Net income: US$2.15m (up 61% from 1Q 2021). Profit margin: 40% (up from 25% in 1Q 2021). Over the next year, revenue is forecast to grow 7.0%, compared to a 7.1% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 45% per year but the company’s share price has only increased by 24% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • Mar 24Investor sentiment improved over the past weekAfter last week's 15% share price gain to €1.64, the stock trades at a forward P/E ratio of 5x. Average forward P/E is 20x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 70% over the past three years.
Reported Earnings • Mar 19Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: EPS: US$0.29 (up from US$0.16 in FY 2020). Revenue: US$21.9m (up 1.6% from FY 2020). Net income: US$7.76m (up 77% from FY 2020). Profit margin: 35% (up from 20% in FY 2020). The increase in margin was primarily driven by lower expenses. Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 8.5%, compared to a 8.2% growth forecast for the pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 45% per year but the company’s share price has only increased by 16% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • Feb 09Investor sentiment improved over the past weekAfter last week's 19% share price gain to €1.45, the stock trades at a forward P/E ratio of 5x. Average forward P/E is 19x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 19% over the past three years.
Valuation Update With 7 Day Price Move • Dec 25Investor sentiment improved over the past weekAfter last week's 16% share price gain to €1.28, the stock trades at a forward P/E ratio of 4x. Average forward P/E is 21x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 25% over the past three years.
Reported Earnings • Nov 12Third quarter 2021 earnings released: EPS US$0.03 (vs US$0.059 in 3Q 2020)The company reported a poor third quarter result with weaker earnings, revenues and profit margins. Third quarter 2021 results: Revenue: US$4.51m (down 6.9% from 3Q 2020). Net income: US$796.0k (down 50% from 3Q 2020). Profit margin: 18% (down from 33% in 3Q 2020). Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has only increased by 12% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • Sep 14Investor sentiment improved over the past weekAfter last week's 17% share price gain to €1.60, the stock trades at a forward P/E ratio of 6x. Average forward P/E is 24x in the Pharmaceuticals industry in Europe. Total loss to shareholders of 23% over the past three years.
Valuation Update With 7 Day Price Move • Aug 19Investor sentiment improved over the past weekAfter last week's 19% share price gain to US$1.34, the stock trades at a forward P/E ratio of 4x. Average forward P/E is 25x in the Pharmaceuticals industry in Europe. Total loss to shareholders of 35% over the past three years.
Reported Earnings • Aug 14Second quarter 2021 earnings released: EPS US$0.11 (vs US$0.015 in 2Q 2020)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: US$6.13m (up 30% from 2Q 2020). Net income: US$2.82m (up US$2.41m from 2Q 2020). Profit margin: 46% (up from 8.7% in 2Q 2020). Over the last 3 years on average, earnings per share has remained flat but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings.
Valuation Update With 7 Day Price Move • Jun 08Investor sentiment improved over the past weekAfter last week's 20% share price gain to US$1.06, the stock trades at a forward P/E ratio of 5x. Average forward P/E is 24x in the Pharmaceuticals industry in Europe. Total loss to shareholders of 38% over the past three years.
Reported Earnings • May 16First quarter 2021 earnings released: EPS US$0.05 (vs US$0.092 in 1Q 2020)The company reported a poor first quarter result with weaker earnings, revenues and profit margins. First quarter 2021 results: Revenue: US$5.45m (down 7.7% from 1Q 2020). Net income: US$1.34m (down 46% from 1Q 2020). Profit margin: 25% (down from 42% in 1Q 2020). Over the last 3 years on average, earnings per share has fallen by 27% per year and the company’s share price has also fallen by 27% per year.
Is New 90 Day High Low • Jan 08New 90-day high: €0.74The company is up 9.0% from its price of €0.68 on 09 October 2020. The German market is up 8.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Pharmaceuticals industry, which is up 11% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €1.71 per share.
Reported Earnings • Nov 14Third quarter 2020 earnings released: EPS US$0.06The company reported a decent third quarter result with improved earnings and profit margins, although revenues were weaker. Third quarter 2020 results: Revenue: US$4.85m (down 16% from 3Q 2019). Net income: US$1.60m (up US$3.79m from 3Q 2019). Profit margin: 33% (up from net loss in 3Q 2019). The move to profitability was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 45% per year whereas the company’s share price has fallen by 40% per year.
Analyst Estimate Surprise Post Earnings • Nov 14Revenue beats expectationsRevenue exceeded analyst estimates by 23%. Over the next year, revenue is expected to shrink by 24% compared to a 2.8% growth forecast for the Pharmaceuticals industry in Germany.
Is New 90 Day High Low • Nov 10New 90-day low: €0.59The company is down 32% from its price of €0.87 on 12 August 2020. The German market is flat over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 2.0% over the same period.
Is New 90 Day High Low • Oct 21New 90-day low: €0.64The company is down 31% from its price of €0.92 on 23 July 2020. The German market is down 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 10.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €2.55 per share.
공시 • Oct 10Cipher Pharmaceuticals Inc. Approves the Appointment of Cathy Steiner as DirectorCipher Pharmaceuticals Inc. announced the voting results for the election of directors at its Annual Meeting of Shareholders held earlier October 8, 2020. The shareholders approved the appointment of Cathy Steiner as director.
Is New 90 Day High Low • Sep 28New 90-day low: €0.69The company is down 10.0% from its price of €0.77 on 30 June 2020. The German market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 4.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €2.58 per share.